Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02920996	Phase II	Merestinib	Merestinib In Non-Small Cell Lung Cancer And Solid Tumors	Terminated	USA	0
NCT07291037	Phase III	Datopotamab deruxtecan Docetaxel	Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (TROPION-Lung17)	Recruiting	USA \| TUR \| POL \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT04140500	Phase I	Tobemstomig	Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors	Active, not recruiting	TUR \| ISR \| GBR \| ESP \| DNK	4
NCT06593522	Phase II	AMG193	A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)	Active, not recruiting	USA \| TUR \| NLD \| LVA \| CZE \| CHE \| CAN \| BRA \| AUS	7
NCT05255302	Phase II	Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL)	Recruiting	FRA	0
NCT01831726	Phase II	Dovitinib	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	USA	0
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| HUN \| GBR \| FRA \| ESP \| CAN \| AUS	3
NCT03093116	Phase Ib/II	Repotrectinib	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Recruiting	USA \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT02279433	Phase I	Taletrectinib	A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	Completed	USA	0
NCT05769075	Phase I	TY-2136b	A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations	Unknown status	USA	0
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Completed	USA \| NZL \| FRA \| ESP \| DNK	1
NCT02568267	Phase II	Entrectinib	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	6
NCT03834961	Phase II	Larotrectinib	Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	Active, not recruiting	USA \| CAN	0
NCT06116682	Phase II	Amivantamab-vmjw	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT06745908	Phase III	Docetaxel Docetaxel + Nogapendekin alfa inbakicept Docetaxel + Nogapendekin alfa inbakicept + Tislelizumab	Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In	Recruiting	USA	0
NCT06031688	Phase II	Tepotinib Ramucirumab + Tepotinib	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT04995523	Phase Ib/II	AZD2936	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)	Active, not recruiting	USA \| NLD \| FRA \| ESP \| DNK \| BRA \| BEL \| AUS	8
NCT05064280	Phase II	Lenvatinib + Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT07603856	Phase II	Pembrolizumab Cemiplimab Ipilimumab + Nivolumab Durvalumab Docetaxel + Ramucirumab Docetaxel + Gemcitabine Docetaxel	A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer (REVIVE)	Recruiting	USA	0
NCT07619339	Phase I	Ivonescimab + Tepotinib	A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT06680050	Phase II	Ceralasertib + Durvalumab	Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL)	Recruiting	ITA \| CHE	0
NCT06119581	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS	7

Profile Name	NTRK2 rearrange
Gene Variant Detail	NTRK2 rearrange (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting